Duration of untreated psychosis: A critical examination of the concept and its importance

Psychological Medicine

Volumn 31, Issue 3, 2001, Pages 381-400

  Norman, Ross M G ^a,b   Malla, Ashok K ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT;

ADULT; AGED; COGNITION; CONTROLLED STUDY; CORRELATION FUNCTION; DEPRESSION; DISEASE DURATION; ELECTROCONVULSIVE THERAPY; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; MALE; MANIC DEPRESSIVE PSYCHOSIS; MEDICAL LITERATURE; PSYCHOSIS; PSYCHOTHERAPY; RELAPSE; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SYMPTOM; TREATMENT OUTCOME;

EID: 0035070861     PISSN: 00332917     EISSN: None     Source Type: Journal    
DOI: 10.1017/s0033291701003488     Document Type: Review

References (87)

1. On prognosis and rehabilitation in schizophrenic and paranoid psychoses. A comparative follow-up study of two series of patients first admitted in 1950 and 1960 respectively
2. Hopelessness and first episode psychosis: A longitudinal study
3. The Comprehensive Assessment of Symptoms and History (CASH): An instrument for assessing, diagnosis and psychopathology
4. Early neuroleptic medication within one year after onset can reduce risk of later relapses in schizophrenia patients
5. A study of the long-term prognosis of schizophrenia under psychotropic drug medication
6. Establishing the onset of psychotic illness
7. Symptomatic and neuropsychological components of defect states
8. Early intervention in schizophrenia
9. Early intervention in psychosis: The critical period hypothesis
10. First person account: Psychosocial implications of stigma caused by misdiagnosis
11. National Institute of Mental Health longitudinal study of chronic schizophrenia: Prognosis and predictors of outcome
12. Determinants of quality of life at first presentation with schizophrenia
13. Prevalence of substance misuse in first episode psychosis
14. Duration of untreated psychosis and 12 month outcome of first episode psychosis: The impact of treatment approach
15. The treatment of acute schizophrenia without drugs: An investigation of some current assumptions
16. Neuropsychological evidence supporting a neurodevelopmental model of schizophrenia: A longitudinal study
17. Is there an association between duration of untreated psychosis and 24-month clinical outcome in a first-admission series?
18. The Northwick Park Study of first episodes of schizophrenia II. A randomized controlled trial of prophylactic neuroleptic treatment
19. Long term depot maintenance of chronic schizophrenic outpatients: The seven year follow-up of the Medical Research Council fluphenazine/placebo trial
20. Pharmacologic treatment of first episode schizophrenia: Early intervention is key to outcome
21. Prolonged recovery in first episode psychosis
22. The Global Assessment Scale: A procedure for measuring overall severity of psychiatric disturbance
23. The role of social relationships in the course of first-episode schizophrenia and affective psychosis
24. Social support predicts 5-year outcome in first episode schizophrenia
25. Early detection and intervention for initial episodes of schizophrenia
26. Early intervention for schizophrenic disorders: Implementing optimal treatment strategies in routine clinical care
27. Course and outcome of schizophrenia
28. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: A hypothesis for the etiology of schizophrenia
29. The Iowa longitudinal study of recent onset psychosis: One year follow-up of first episode patients
30. Premorbid and onset features of first episode schizophrenia
31. Delay to first antipsychotic medication in schizophrenia: Impact on symptomatology and clinical course of illness
32. IRAOS: An instrument for the assessment of onset and early course of schizophrenia
33. The influence of age and sex on the onset and early course of schizophrenia
34. The Quality of Life Scale: An instrument for rating the schizophrenic deficit syndrome
35. Twenty years' follow-up of first psychiatric presentation for schizophrenia: What could have been prevented?
36. Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: Double blind placebo trial
37. Untreated initial psychosis: Its relation to quality of life and symptom remission in first episode schizophrenia
38. WHO collaborative study on impairments and disabilities associated with schizophrenic disorders
39. Early intervention and prevention in schizophrenia - Experiences from a study in Stavanger, Norway
40. The discontinuance of maintenance neuroleptic therapy in chronic schizophrenia patients: Drug and social consequences
41. Development, disease and degeneration in schizophrenia: A unitary pathophysiological model
42. First-episode schizophrenia 1: Early course parameters
43. First episode schizophrenia with long duration of untreated psychosis: Pathways to care
44. Prospective study of psychobiology in first-episode schizophrenia at Hillside Hospital
45. Endogenous neurochemical sensitization in the pathophysiology of schizophrenia deficits and dysfunction in neuronal regulation and plasticity
46. Early intervention, untreated psychosis and the course of early schizophrenia
47. Duration of psychosis and outcome in first episode schizophrenia
48. A ten year follow-up study of Chinese schizophrenics in Hong Kong
49. Early detection and intervention in schizophrenia: Research
50. Duration of untreated psychosis in first episode schizophrenia: Master of determinant of course?
51. Early detection and intervention with schizophrenia: Rationale
52. The Royal Park Multidiagnostic Instrument for Psychosis. Development, reliability and validity
53. EPPIC: An evolving system of early detection and optimal management
54. Outcome of treatment of schizophrenia in a North-East Scottish mental hospital
55. Progressive atrophy of the frontal lobes in first episode schizophrenia: Interaction with clinical course and neuroleptic treatment
56. Improving outcome in schizophrenia: The case for early intervention
57. Insulin and chlorpromazino in schizophrenia: A ten year comparative survey
58. Schizophrenia- A follow-up study of results of treatment
59. Schizophrenia: A follow-up study of the results of five forms of treatment
60. Dimensions of outcome with clozapine
61. Neuro-psychological correlates of syndromes in schizophrenia
62. Pattern of discharge from Norwegian psychiatric hospitals before and after the introduction of psychotropic drugs
63. Glutamate receptor dysfunction and schizophrenia
64. First admitted schizophrenics in drug era
65. Prognosis of schizophrenia before and after pharmacotherapy: I. Short-term outcome
66. Prognosis of schizophrenia before and after pharmacotherapy: II. Three year follow-up
67. Outcome study of first-episode psychosis, I: Relapse rates after 1 year
68. Are there schizophrenics for whom drugs may be unnecessary or contradicted?
69. Confronting the confounders: The meaning, detection and treatment of confounders in research
70. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder
71. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder
72. Long-term follow-up of schizophrenia in 16 countries: A description of the International Study of Schizophrenia conducted by the World Health Organization
73. One year after discharge: Community adjustment of schizophrenic patients
74. Psychopathology, executive (frontal) and general cognitive impairment in relation to duration of initially untreated vs. subsequently treated psychosis in chronic schizophrenia
75. Phenomenology and functioning in first episode schizophrenia
76. Long-term follow-up study of schizophrenic patients
77. Course of treatment response in first episode and chronic schizophrenia
78. The McLean first-episode psychosis project: Six months recovery and recurrence outcome
79. Early detection and intervention in schizophrenia: Unsolved questions
80. Prediction of duration of psychosis before first admission
81. Sequential cross-sectional and 10 year prospective study of severe negative symptoms in relation to duration of initially untreated psychosis in chronic schizophrenia
82. The natural history of schizophrenia: A five year prospective follow-up of a representative sample of schizophrenics by means of a standardized clinical and social assessment
83. Natural course of schizophrenic disorders: A 15 year follow-up of a Dutch incidence cohort
84. Neuroleptics and the natural course of schizophrenia
85. Long-term morbidity associated with delayed treatment of first admission schizophrenic patients: A re-analysis of the Camarillo State Hospital data